Aziyo Biologics, Inc. – NASDAQ:AZYO
Aziyo Biologics stock price monthly change
Aziyo Biologics stock price quarterly change
Aziyo Biologics stock price yearly change
Aziyo Biologics key metrics
Market Cap | 24.21M |
Enterprise value | 34.32M |
P/E | -0.59 |
EV/Sales | 0.46 |
EV/EBITDA | -0.92 |
Price/Sales | 0.26 |
Price/Book | -3.87 |
PEG ratio | 0.53 |
EPS | -2.09 |
Revenue | 42.13M |
EBITDA | -19.32M |
Income | -33.78M |
Revenue Q/Q | -50.54% |
Revenue Y/Y | -11.06% |
Profit margin | -68.8% |
Oper. margin | -61.88% |
Gross margin | 38.74% |
EBIT margin | -61.88% |
EBITDA margin | -45.87% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAziyo Biologics stock price history
Aziyo Biologics stock forecast
Aziyo Biologics financial statements
| Dec 2022 | 12.66M | -5.44M | -42.95% |
|---|---|---|---|
| Mar 2023 | 13.05M | -7.97M | -61.1% |
| Jun 2023 | 10.29M | -10.62M | -103.16% |
| Sep 2023 | 6.12M | -9.74M | -159.08% |
| 2023-11-13 | -0.56 | -0.57276 |
|---|
| Dec 2022 | 68841000 | 73.87M | 107.31% |
|---|---|---|---|
| Mar 2023 | 60630000 | 72.80M | 120.08% |
| Jun 2023 | 52329000 | 74.45M | 142.29% |
| Sep 2023 | 54580000 | 84.05M | 154% |
| Dec 2022 | -5.24M | -134K | 14.26M |
|---|---|---|---|
| Mar 2023 | -5.16M | -182K | 148K |
| Jun 2023 | -2.38M | -85K | -19K |
| Sep 2023 | -312K | 0 | 0 |
Aziyo Biologics alternative data
| Aug 2023 | 144 |
|---|---|
| Sep 2023 | 151 |
| Oct 2023 | 151 |
| Nov 2023 | 151 |
| Dec 2023 | 151 |
| Jan 2024 | 151 |
| Feb 2024 | 151 |
| Mar 2024 | 151 |
| Apr 2024 | 151 |
| Jun 2024 | 151 |
| Jul 2024 | 151 |
Aziyo Biologics other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2022 | 768098 | 0 |
| Mar 2023 | 140000 | 289 |
| Patent |
|---|
Application Filling date: 24 Feb 2021 Issue date: 2 Sep 2021 |
Application Filling date: 22 Jan 2018 Issue date: 5 Dec 2019 |
| Quarter | Transcript |
|---|---|
| Q2 2023 20 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 14 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 22 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 15 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Ronald K. Lloyd (1961) Chief Executive Officer, Pres & Director | $890,570 |
Dr. Jerome Riebman FACC, M.A., M.D. (1954) Chief Medical Officer | $552,690 |
| Dr. Darryl Roberts Ph.D. (1961) Executive Vice President of Operations & Product Devel. | $468,240 |
-
When is Aziyo Biologics's next earnings date?
Unfortunately, Aziyo Biologics's (AZYO) next earnings date is currently unknown.
-
Does Aziyo Biologics pay dividends?
No, Aziyo Biologics does not pay dividends.
-
How much money does Aziyo Biologics make?
Aziyo Biologics has a market capitalization of 24.21M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3.79% to 49.19M US dollars. Aziyo Biologics made a loss 32.9M US dollars in net income (profit) last year or -$0.57 on an earnings per share basis.
-
What is Aziyo Biologics's stock symbol?
Aziyo Biologics, Inc. is traded on the NASDAQ under the ticker symbol "AZYO".
-
What is Aziyo Biologics's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Aziyo Biologics?
Shares of Aziyo Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aziyo Biologics's key executives?
Aziyo Biologics's management team includes the following people:
- Mr. Ronald K. Lloyd Chief Executive Officer, Pres & Director(age: 64, pay: $890,570)
- Dr. Jerome Riebman FACC, M.A., M.D. Chief Medical Officer(age: 71, pay: $552,690)
- Dr. Darryl Roberts Ph.D. Executive Vice President of Operations & Product Devel.(age: 64, pay: $468,240)
-
How many employees does Aziyo Biologics have?
As Jul 2024, Aziyo Biologics employs 151 workers.
-
When Aziyo Biologics went public?
Aziyo Biologics, Inc. is publicly traded company for more then 4 years since IPO on 8 Oct 2020.
-
What is Aziyo Biologics's official website?
The official website for Aziyo Biologics is aziyo.com.
-
Where are Aziyo Biologics's headquarters?
Aziyo Biologics is headquartered at 12510 Prosperity Drive, Silver Spring, MD.
-
How can i contact Aziyo Biologics?
Aziyo Biologics's mailing address is 12510 Prosperity Drive, Silver Spring, MD and company can be reached via phone at +240 2471170.
Aziyo Biologics company profile:
Aziyo Biologics, Inc.
aziyo.comNASDAQ
151
Medical - Devices
Healthcare
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons. In addition, it offers Fiber VBM, ViBone, and OsteGro V that are human tissue-derived bone allografts designed to protect and preserve native bone cells; and SimpliDerm, a pre-hydrated HADM designed to repair or replacement of damaged or inadequate integumental tissues. Further, the company provides contract manufacturing services for various products to corporate customers. It sells its products to hospitals and other healthcare facilities through its direct sales force, commercial partners, and independent sales agents. The company was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Silver Spring, MD 20904
CIK: 0001708527
ISIN: US05479K1060
CUSIP: 05479K106
